TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter f701: f7Drug f7Definitions, f7Standards, f7and f7Information f7Sources
f7Willihnganz: f7Clayton’s f7Basic f7Pharmacology f7 for f7Nurses, f719th f7Edition
MULTIPLE
f7CHOICE
1. Which f7name f7identifies f7a f7drug f7listed f7by f7the f7US
f7Food f7and7fDrug f7Administration f7(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: f7 C
The f7official f7name f7is f7the f 7 name f7under f7which f7a f7drug
f7is f7listed f7by f7the f7FDA. f7The f7brand f7name, f7or f7trademark,
f7is f7the f7name f7given f7to f7a f7drug f7by f7its f7manufacturer. f7The
f7nonproprietary, f7or f7generic, f7name f7is f7provided f7by f7the
f7United f7States f7Adopted f7Names f7Council.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f79
OBJ: f71NAT: f7NCLEX f7Client f7Needs f7Category: f7Safe,
f7Effective f7Care7fEnvironment f7TOP: f 7 Nursing f7Process f7Step:
f7Assessment CON:
f7Patient f7Education
2. Which f7source f7contains f7information f7specific f7to f7nutritional f7supplements?
a. USP f7Dictionary f7of f7USAN f 7 &f7International f7Drug f7Names
b. Natural f7Medicines f7Comprehensive f7Database
c. United f7States f7Pharmacopoeia/National f7Formulary f7(USP f7NF)
d. Drug f7Interaction f7Facts
ANS: f7 C
United f7States f7Pharmacopoeia/National f7Formulary f7contains f7information f7specific f7to
f7nutritional7fsupplements. f7USP f7Dictionary f7of f7USAN f7& f7International f7Drug f7Names f7is f7a
f7compilation f7of f7drugf7names, f7pronunciation f7guide, f7and f7possible f7future f7FDA f7approved
f7drugs; f7it f7does f7not f7include f7nutritional f7supplements. f7 Natural f7Medicines f7Comprehensive
f7Database f7contains
evidence-based f7information f7on f7herbal f7medicines f7and f7herbal f7combination f7products; f7it
f7does f7not7finclude f7information f7specific f7to f7nutritional f7supplements. f7Drug f7Interaction
f7Facts f7contains f7comprehensive f7information f7on f7drug f7 interaction f7facts; f7it f7 does f7not
f7 include f7nutritional f7supplements.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f74 OBJ:
f737fNAT: f 7 NCLEX f7Client f7Needs f7 Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Assessment CON: f 7 Nutrition f7| f7Patient f7Education
3. Which f7drug f7reference f7contains f7drug f7monographs f7that f7describe f7all f7drugs f7in f7a f7therapeutic f7class?
a. Drug f7Facts f7and f7Comparisons
,Test f7Bank f7For f7Clayton’s f7Basic f7Pharmacology f7for f7Nurses f719th 3
f7Edition
b. Drug f7Interaction f7Facts
c. Handbook f7on f7Injectable f7Drugs
d. Martindale—The f7Complete f7Drug f7Reference
ANS: f7 A
Drug f7Facts f7and f7Comparisons f7contains f7drug f7monographs f7that f7describe f7all
f7drugs f7in f7af7therapeutic f7class. f7Monographs f7are f7formatted f7as f7tables f7to f7allow
f7comparison f7of f7similar7fproducts, f7brand f7names, f7manufacturers, f7cost f7indices, f7and
f7available f7dosage f7forms f7Online f7version f7is f7available.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f74 f7Table f71.2
OBJ: f7 f7 f 7 3 NAT: f 7 NCLEX f7Client f7Needs f7Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Assessment CON: f 7 Safety f7| f7Patient f7Education f7| f7Clinical f7Judgment
4. Which f7drug f7reference f7contains f7 monographs f7about f7 virtually f7everyf7single-entityf7drug
available7fin f7the f7United f7States f7and f7describes f7therapeutic f7uses f7of f7drugs, f7including
f7
approved f7and f7unapproved f7uses?
f7
a. Martindale: f7The f7Complete f7Drug f7Reference
b. AHFS f7Drug f7Information
c. Drug f7Reference
d. Drug f7Facts f7and f7Comparisons
ANS: f7 B
AHFS f7Drug f7Information f7contains f7monographs f7about f7virtually f7every f7single-entity f7drug
f7available f7in f7the f7United f7States f7and f7describes f7therapeutic f7uses f7of f7drugs, f7 including
f7approved f7and7funapproved f7uses.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f74 f7Table f71.2
OBJ: f7 f7 f 7 3 NAT: f 7 NCLEX f7Client f7Needs f7Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Planning CON: f 7 Safety f7| f7Patient f7Education f7| f7Clinical f7Judgment
5. Which f7online f7drug f7reference f7makes f7available f7to f7healthcare f7providers f7and f7the
f7public f7a f7standard, f7comprehensive, f7up-to-date f7look f7up f7and f7downloadable f7resource
f7about f7medicines?
a. American f7Drug f7Index
b. American f7Hospital f7Formulary
c. DailyMed
d. Drug f7Reference
ANS: f7 C
DailyMed f7makes f7available f7to f7healthcare f7providers f7and f7the f7public f7a f7standard,
f7comprehensive,7fup-to-date f7look f7up f7and f7downloadable f7resource f7about f7medicines. f7The
f7American f7Drug f7Index f7is7fnot f7appropriate f7for f7patient f7use. f7The f7American f7Hospital
f7Formulary f7is f7not f7appropriate f7for f7patient f7 use. f7The f7drug f7reference f7 is f7 not
f7 appropriate f7for f7patient f7 use.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f73 f7| f7p. f74 OBJ:
f737fNAT: f 7 NCLEX f7Client f7Needs f7 Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Implementation
CON: f 7 Safety f7| f7Patient f7Education f7| f7Clinical f7Judgment
6. Which f7legislation f7authorizes f7the f7FDA f7to f7determine f7the f7safetyf7of f7a f7drug f7before f7its f7marketing?
a. Federal f7Food, f7Drug, f7and f7Cosmetic f7Act f7(1938)
b. Durham f7Humphrey f7Amendment f7 (1952)
, Test f7Bank f7For f7Clayton’s f7Basic f7Pharmacology f7for f7Nurses f719th 4
f7Edition
c. Controlled f7Substances f7Act f7(1970)
d. Kefauver f7Harris f7Drug f7Amendment f7(1962)
ANS: f7 A
The f7Federal f7Food, f7Drug, f7and f7Cosmetic f7Act f7of f71938 f7authorized f7the f7FDA f7to
f7determine f7the f7safety f7of f7all f7drugs f7before f7marketing. f7Later f7amendments f7and f7acts
f7helped f7tighten f7FDA f7control f7and f7ensure f7drug f7safety. f7The f7Durham f7Humphrey
f7Amendment f7defines f7the f7kinds f7of f7drugs f7that f7 cannot f7be f7used f7safely f7without f7medical
f7supervision f7and f7restricts f7their f7sale f7to f7prescription f7by f7a f7licensed f7practitioner. f7The
f7Controlled f7Substances f7Act f7addresses f7only f7controlled f7substances f7and7ftheir
f7categorization. f7The f7Kefauver f7Harris f7Drug f7Amendment f7ensures f7drug f7efficacy f7and
f7greater7fdrug f7safety. f7Drug f7manufacturers f7are f7required f7to f7prove f7to f7the f7FDA f7the
f7effectiveness f7of f7their f7products f7before f7marketing f7them.
DIF: Cognitive f7Level: f7Knowledge REF: f7p. f7 5 f7Table f7l.3
OBJ: f 7 5 NAT: f7NCLEX f7Client f7Needs f7Category: f7Physiological
f7Integrity7fTOP: f 7 Nursing f7Process f7 Step: f7Assessment
CON: f 7 Safety f7| f7Patient f7Education f7| f7Evidence f7| f7Health f7Care f7Law
7. Which f7classification f7does f7meperidine f7(Demerol) f7fall f7under?
a. I
b. II
c. III
d. IV
ANS: f7 B
Meperidine f7(Demerol) f7is f7a f7Schedule f7II f7drug; f7it f7has f7a f7high f7potential f7for f7abuse f7and
f7may f7lead f7to7fsevere f7psychological f7and f7physical f7dependence. f7Schedule f7I f7drugs f7have
f7high f7potential f7for f7abuse7fand f7no f7recognized f7medical f7use. f7Schedule f7III f7drugs f7have
f7some f7potential f7for f7abuse. f7Use f7may f7lead f7to f7low f7to f7moderate f7physical f7dependence f7or
f7high f7psychological f7dependence. f7Schedule f7 IV7fdrugs f7have f7low f7potential f7for f7abuse. f7Use
f7may f7lead f7to f7limited f7physical f7or f7psychological f7dependence.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f710 OBJ:
f727fNAT: f 7 NCLEX f7Client f7Needs f7Category: f7Safe, f7Effective f7Care
f7Environment
TOP: f 7 Nursing f7Process f7Step: f7Assessment CON: f 7 Patient f7Education f7| f7Addiction f7| f7Pain
8. Which f7action f7would f7the f7FDA f7take f7to f7expedite f7drug f7development f7 and f7approval f7for f7an
f7outbreakf7of f7smallpox?
a. List f7smallpox f7as f7a f7health f7orphan f7disease.
b. Omit f7the f7preclinical f7research f7phase.
c. Extend f7the f7clinical f7research f7phase.
d. Fast f7track f7the f7investigational f7drug.
ANS: f7 D
Once f7the f7Investigational f7New f7Drug f7Application f7has f7been f7approved, f7the f7drug f7can
f7receive f7highest f7priority f7within f7the f7agency, f7which f7is f7called f7fast f7tracking. f7A f7smallpox
f7outbreak f7would f7become f7a f7priority f7concern f7in f7the f7world. f7Orphan f7diseases f7are f7not
f7researched f7in f7a f7priority f7manner. f7Preclinical f7research f7is f7not f7omitted. f7Extending f7any
f7phase f7of f7the f7research f7would f7mean7fa f7longer f7time f7to f7develop f7a f7vaccine. f7The f7FDA f7must
f7ensure f7that f7all f7phases f7of f7the f7preclinical f7and7fclinical f7research f7phase f7 have f7 been
f7completed f7in f7a f7safe f7manner.
DIF: Cognitive f7Level: f7Knowledge REF: f7 f7 f7p. f77 OBJ: f 7 5
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter f701: f7Drug f7Definitions, f7Standards, f7and f7Information f7Sources
f7Willihnganz: f7Clayton’s f7Basic f7Pharmacology f7 for f7Nurses, f719th f7Edition
MULTIPLE
f7CHOICE
1. Which f7name f7identifies f7a f7drug f7listed f7by f7the f7US
f7Food f7and7fDrug f7Administration f7(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: f7 C
The f7official f7name f7is f7the f 7 name f7under f7which f7a f7drug
f7is f7listed f7by f7the f7FDA. f7The f7brand f7name, f7or f7trademark,
f7is f7the f7name f7given f7to f7a f7drug f7by f7its f7manufacturer. f7The
f7nonproprietary, f7or f7generic, f7name f7is f7provided f7by f7the
f7United f7States f7Adopted f7Names f7Council.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f79
OBJ: f71NAT: f7NCLEX f7Client f7Needs f7Category: f7Safe,
f7Effective f7Care7fEnvironment f7TOP: f 7 Nursing f7Process f7Step:
f7Assessment CON:
f7Patient f7Education
2. Which f7source f7contains f7information f7specific f7to f7nutritional f7supplements?
a. USP f7Dictionary f7of f7USAN f 7 &f7International f7Drug f7Names
b. Natural f7Medicines f7Comprehensive f7Database
c. United f7States f7Pharmacopoeia/National f7Formulary f7(USP f7NF)
d. Drug f7Interaction f7Facts
ANS: f7 C
United f7States f7Pharmacopoeia/National f7Formulary f7contains f7information f7specific f7to
f7nutritional7fsupplements. f7USP f7Dictionary f7of f7USAN f7& f7International f7Drug f7Names f7is f7a
f7compilation f7of f7drugf7names, f7pronunciation f7guide, f7and f7possible f7future f7FDA f7approved
f7drugs; f7it f7does f7not f7include f7nutritional f7supplements. f7 Natural f7Medicines f7Comprehensive
f7Database f7contains
evidence-based f7information f7on f7herbal f7medicines f7and f7herbal f7combination f7products; f7it
f7does f7not7finclude f7information f7specific f7to f7nutritional f7supplements. f7Drug f7Interaction
f7Facts f7contains f7comprehensive f7information f7on f7drug f7 interaction f7facts; f7it f7 does f7not
f7 include f7nutritional f7supplements.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f74 OBJ:
f737fNAT: f 7 NCLEX f7Client f7Needs f7 Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Assessment CON: f 7 Nutrition f7| f7Patient f7Education
3. Which f7drug f7reference f7contains f7drug f7monographs f7that f7describe f7all f7drugs f7in f7a f7therapeutic f7class?
a. Drug f7Facts f7and f7Comparisons
,Test f7Bank f7For f7Clayton’s f7Basic f7Pharmacology f7for f7Nurses f719th 3
f7Edition
b. Drug f7Interaction f7Facts
c. Handbook f7on f7Injectable f7Drugs
d. Martindale—The f7Complete f7Drug f7Reference
ANS: f7 A
Drug f7Facts f7and f7Comparisons f7contains f7drug f7monographs f7that f7describe f7all
f7drugs f7in f7af7therapeutic f7class. f7Monographs f7are f7formatted f7as f7tables f7to f7allow
f7comparison f7of f7similar7fproducts, f7brand f7names, f7manufacturers, f7cost f7indices, f7and
f7available f7dosage f7forms f7Online f7version f7is f7available.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f74 f7Table f71.2
OBJ: f7 f7 f 7 3 NAT: f 7 NCLEX f7Client f7Needs f7Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Assessment CON: f 7 Safety f7| f7Patient f7Education f7| f7Clinical f7Judgment
4. Which f7drug f7reference f7contains f7 monographs f7about f7 virtually f7everyf7single-entityf7drug
available7fin f7the f7United f7States f7and f7describes f7therapeutic f7uses f7of f7drugs, f7including
f7
approved f7and f7unapproved f7uses?
f7
a. Martindale: f7The f7Complete f7Drug f7Reference
b. AHFS f7Drug f7Information
c. Drug f7Reference
d. Drug f7Facts f7and f7Comparisons
ANS: f7 B
AHFS f7Drug f7Information f7contains f7monographs f7about f7virtually f7every f7single-entity f7drug
f7available f7in f7the f7United f7States f7and f7describes f7therapeutic f7uses f7of f7drugs, f7 including
f7approved f7and7funapproved f7uses.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f74 f7Table f71.2
OBJ: f7 f7 f 7 3 NAT: f 7 NCLEX f7Client f7Needs f7Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Planning CON: f 7 Safety f7| f7Patient f7Education f7| f7Clinical f7Judgment
5. Which f7online f7drug f7reference f7makes f7available f7to f7healthcare f7providers f7and f7the
f7public f7a f7standard, f7comprehensive, f7up-to-date f7look f7up f7and f7downloadable f7resource
f7about f7medicines?
a. American f7Drug f7Index
b. American f7Hospital f7Formulary
c. DailyMed
d. Drug f7Reference
ANS: f7 C
DailyMed f7makes f7available f7to f7healthcare f7providers f7and f7the f7public f7a f7standard,
f7comprehensive,7fup-to-date f7look f7up f7and f7downloadable f7resource f7about f7medicines. f7The
f7American f7Drug f7Index f7is7fnot f7appropriate f7for f7patient f7use. f7The f7American f7Hospital
f7Formulary f7is f7not f7appropriate f7for f7patient f7 use. f7The f7drug f7reference f7 is f7 not
f7 appropriate f7for f7patient f7 use.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f73 f7| f7p. f74 OBJ:
f737fNAT: f 7 NCLEX f7Client f7Needs f7 Category: f7Physiological f7Integrity
TOP: f 7 Nursing f7Process f7Step: f7Implementation
CON: f 7 Safety f7| f7Patient f7Education f7| f7Clinical f7Judgment
6. Which f7legislation f7authorizes f7the f7FDA f7to f7determine f7the f7safetyf7of f7a f7drug f7before f7its f7marketing?
a. Federal f7Food, f7Drug, f7and f7Cosmetic f7Act f7(1938)
b. Durham f7Humphrey f7Amendment f7 (1952)
, Test f7Bank f7For f7Clayton’s f7Basic f7Pharmacology f7for f7Nurses f719th 4
f7Edition
c. Controlled f7Substances f7Act f7(1970)
d. Kefauver f7Harris f7Drug f7Amendment f7(1962)
ANS: f7 A
The f7Federal f7Food, f7Drug, f7and f7Cosmetic f7Act f7of f71938 f7authorized f7the f7FDA f7to
f7determine f7the f7safety f7of f7all f7drugs f7before f7marketing. f7Later f7amendments f7and f7acts
f7helped f7tighten f7FDA f7control f7and f7ensure f7drug f7safety. f7The f7Durham f7Humphrey
f7Amendment f7defines f7the f7kinds f7of f7drugs f7that f7 cannot f7be f7used f7safely f7without f7medical
f7supervision f7and f7restricts f7their f7sale f7to f7prescription f7by f7a f7licensed f7practitioner. f7The
f7Controlled f7Substances f7Act f7addresses f7only f7controlled f7substances f7and7ftheir
f7categorization. f7The f7Kefauver f7Harris f7Drug f7Amendment f7ensures f7drug f7efficacy f7and
f7greater7fdrug f7safety. f7Drug f7manufacturers f7are f7required f7to f7prove f7to f7the f7FDA f7the
f7effectiveness f7of f7their f7products f7before f7marketing f7them.
DIF: Cognitive f7Level: f7Knowledge REF: f7p. f7 5 f7Table f7l.3
OBJ: f 7 5 NAT: f7NCLEX f7Client f7Needs f7Category: f7Physiological
f7Integrity7fTOP: f 7 Nursing f7Process f7 Step: f7Assessment
CON: f 7 Safety f7| f7Patient f7Education f7| f7Evidence f7| f7Health f7Care f7Law
7. Which f7classification f7does f7meperidine f7(Demerol) f7fall f7under?
a. I
b. II
c. III
d. IV
ANS: f7 B
Meperidine f7(Demerol) f7is f7a f7Schedule f7II f7drug; f7it f7has f7a f7high f7potential f7for f7abuse f7and
f7may f7lead f7to7fsevere f7psychological f7and f7physical f7dependence. f7Schedule f7I f7drugs f7have
f7high f7potential f7for f7abuse7fand f7no f7recognized f7medical f7use. f7Schedule f7III f7drugs f7have
f7some f7potential f7for f7abuse. f7Use f7may f7lead f7to f7low f7to f7moderate f7physical f7dependence f7or
f7high f7psychological f7dependence. f7Schedule f7 IV7fdrugs f7have f7low f7potential f7for f7abuse. f7Use
f7may f7lead f7to f7limited f7physical f7or f7psychological f7dependence.
DIF: Cognitive f7Level: f7Knowledge REF: f 7 p. f710 OBJ:
f727fNAT: f 7 NCLEX f7Client f7Needs f7Category: f7Safe, f7Effective f7Care
f7Environment
TOP: f 7 Nursing f7Process f7Step: f7Assessment CON: f 7 Patient f7Education f7| f7Addiction f7| f7Pain
8. Which f7action f7would f7the f7FDA f7take f7to f7expedite f7drug f7development f7 and f7approval f7for f7an
f7outbreakf7of f7smallpox?
a. List f7smallpox f7as f7a f7health f7orphan f7disease.
b. Omit f7the f7preclinical f7research f7phase.
c. Extend f7the f7clinical f7research f7phase.
d. Fast f7track f7the f7investigational f7drug.
ANS: f7 D
Once f7the f7Investigational f7New f7Drug f7Application f7has f7been f7approved, f7the f7drug f7can
f7receive f7highest f7priority f7within f7the f7agency, f7which f7is f7called f7fast f7tracking. f7A f7smallpox
f7outbreak f7would f7become f7a f7priority f7concern f7in f7the f7world. f7Orphan f7diseases f7are f7not
f7researched f7in f7a f7priority f7manner. f7Preclinical f7research f7is f7not f7omitted. f7Extending f7any
f7phase f7of f7the f7research f7would f7mean7fa f7longer f7time f7to f7develop f7a f7vaccine. f7The f7FDA f7must
f7ensure f7that f7all f7phases f7of f7the f7preclinical f7and7fclinical f7research f7phase f7 have f7 been
f7completed f7in f7a f7safe f7manner.
DIF: Cognitive f7Level: f7Knowledge REF: f7 f7 f7p. f77 OBJ: f 7 5
